Summarv The aim of this study was to investigate mechanisms of anti-tumour activity and necrosis induced bv combinations of tumour necrosis factor alpha (TNF-x) and interferon gamma (IFN-y) The concept of inducing haemorrhagic necrosis to treat tumours was first investigated systematically by Coley (1893). However, it was not until 1975 that a tumour-necrosing activity in the sera of BCG-pnrmed endotoxin treated mice was isolated (Carswell et al.. 1975) . Since then, two molecules responsible for this activity. TNF-a (cachectin) and TNF-P (lymphotoxin). have been purified, cloned, and produced in large amounts by recombinant technology (reviewed in Beutler. 1992). Their availability allowed extensive studies, both in animal models and clinical trials. Although initially TNF--a was hailed as a potent anti-tumour treatment, it later proved to induce only modest tumour responses accompanied by unacceptable side-effects (Feinberg et al., 1988) . Moreover, endogenous TNF-a has also been implicated in tumour progression, particularly in ovarian cancer (Naylor et al., 1993) .
The concept of inducing haemorrhagic necrosis to treat tumours was first investigated systematically by Coley (1893). However, it was not until 1975 that a tumour-necrosing activity in the sera of BCG-pnrmed endotoxin treated mice was isolated (Carswell et al.. 1975) . Since then, two molecules responsible for this activity. TNF-a (cachectin) and TNF-P (lymphotoxin). have been purified, cloned, and produced in large amounts by recombinant technology (reviewed in Beutler. 1992). Their availability allowed extensive studies, both in animal models and clinical trials. Although initially TNF--a was hailed as a potent anti-tumour treatment, it later proved to induce only modest tumour responses accompanied by unacceptable side-effects (Feinberg et al., 1988) . Moreover, endogenous TNF-a has also been implicated in tumour progression, particularly in ovarian cancer (Naylor et al., 1993) .
Potentiation of the anti-tumour actions of TNF--x was obtained with IFN-y in a variety of murine tumours and human tumour xenografts (Brouckaert et al., 1986; Fransen et al.. 1986; Balkwill et al., 1987) . Later, Thom et al. (1992) reported improvement of the anti-tumour effect and higher cure rate of MCA sarcomas treated with paralesional administration of TNF-a. together with IFN-y. In recent clinical experiments, high doses of locoregional TNF-a. combined with systemic IFN-a and local chemotherapy, mediated specific destruction of tumour vasculature, and complete tumour regression, in a majority of patients with melanoma, squamous cell carcinoma and soft tissue sarcoma, whose tumours are accessible to isolated limb perfusion (ILP) (Lienard et al., 1992; Eggermont et al., 1993) . The impressive anti-tumour effects of this treatment seem to be associated with vascular-mediated damage (Renard et al.. 1994 ). This treatment however remains controversial: other groups using the same procotol have been unable to obtain similar results (Vaglini et al., 1994) .
These studies led us to develop an animal model reproducing some of the observed effects of TNF-a and IFN-y human vascular administration of human TNF-a and human IFN-y in a human host vs intratumoural injections of human TNF-x and systemic administration of rat IFN-y in an immunocompromised mouse. However, we used a xenogeneic system to permit dissociation between effects on host and tumour cells. We examined the actions of TNF-a and IFN-y on tumour necrosis, tumour growth and survival. Histological changes were monitored and expression of stromal cytokine, cytokine receptor and adhesion molecule mRNA were followed within the murine host.
Materials and methods

Mice
Female pathogen-free nu nu mice of mixed genetic background were bred by the Imperial Cancer Research Fund animal breeding unit, Clare Hall, Potters Bar, UK. They were housed in negative pressure isolators and used for experiments when 6-9 weeks old.
Tumours
The human breast mucoid carcinoma 1068 was originally derived from a primary tumour (Balkwill et al., 1986) and maintained by passage in mice at 6-8 week intervals.
Cvtokines
Recombinant human TNF-a kindly provided by BASF Knoll (Maidenhead, Berkshire, UK), was more than 99% pure and contained less than 0.125 EU mg-' endotoxin. The sp. act. was 5 x 107 units mg-'. Recombinant rat IFN-y was provided by Roussel UCLAF (Romainville, France). It had a sp.
act. of I x 107 units mg-1. Endotoxin levels were less than 0.367 EU mg-'. TNF-a and IFN-y were diluted to the appropnate concentration with calcium-and magnesium-free phosphate-buffered saline (PBS) containing 3 mg ml-i bovine serum albumin (BSA; Sigma, Dorset, UK) and stored in single dose aliquots at -70'C.
An"mour ds od TNF-e and IFN-y in nv 60'C for 1 min and 72'C for 10 mmn. PCR was carried out in an automated DNA Thermal Cycler (Techne, Cambnrdge, UK). in the presence of 0.2!um of each pnrmer. The following pnmers were used: GAPDH 1. 5'-TGA AGG TCG GTG TGA ACG GAT TTG G-3' GADPH 2. 5'-ACG ACA TAC TCA GCA CCA GCA TCA C-3' TNF-a 1. 5'-CCC GAC TAC GTG CTC CTC-3' TNF-a 2. 5'-GAC CTG CCC GGA CTC CGC-3' TNF receptor 55 kDa 1. 5'-CCG GGC CAC CTG GTC CG-3' TNF receptor 55 kDa 2. 5'-CAA GTA GGT TCC TTT GTG-3' TNF receptor 75 kDa 1. 5'-GAC GAA TTC ATG GAG TAG GCC TTG AGC-3' TNF receptor 75 kDa 2. 5'-TAA GGA TCC CTG AGA CGG ACA CTC CTC-3' ICAM-1 15' CAA CTG GAA GCT GTT TGA GCT G-3' ICAM-1 2 5'-TAG CTG GAA GAT CGA AAG TCC G-3' VCAM-1 1 5'-CAA GGG TGA CCA GCT CAT GA-3' VCAM-1 2 5'-TGT GCA GCC ACC TGA GAT CC-3' P-Selectin 1 5'-ACG AGC TGG ACG GAC CCG-3' P-Selectin 2 5'-GGC TGG CAC TCA AAT TTA CAG C-3'
The glyceraldehyde phosphatase dehydrogenase (GAPDH) primers recognise both human and murine GAPDH. the remaining primers are all based on published murine sequences. IL-6 primers were purchased from Clontech (Clontech Laboratories. Palo Alto, CA, USA). One-half of the reaction was electrophoresed on I1% agarose gels and the appropriate bands revealed by ethidium bromide staining of the gel.
Relative quantitation was achieved by subjecting parallel samples to amplification in subsaturating conditions of the constitutively expressed GAPDH gene and the specific cytokine. receptor or adhesion molecule. The relative product amounts were quantitated by measuring the incorporated radioactivity of the specific bands from dried gels with a Molecular Dynamics 400A Phosphorlmager. The values obtained for each cytokine were normalised to the values obtained by measuring the incorporated radioactivity in the corresponding GAPDH amplification products. Under the conditions used there was a linear relationship between the initial amount of RNA and the PCR signal.-It should be emphasised however that this protocol does not allow for a precise determination of the exact amount of mRNA molecules present in each sample.
Statistical analysis
The data were analysed for statistical significance between groups using the Student's t-test; (two-tailed). Differences in survival times were calculated by ANOVA.
Results
Effect of TNF-c and IFN-y on necrosis, tumour grow-th and survival We first measured the effects of varying doses of human TNF-x and rat IFN-y on macroscopic necrosis, tumour growth and treatment-related mortality (Table I) . Only mice receiving IFN-y in combination with TNF-a showed overt haemorrhagic tumour necrosis which appeared approximately 2 weeks after beginning the treatment. Mice injected with the highest TNF-a and IFN-y doses (5 jig TNF-a and 50 x 103 U IFN-y) developed generalised vascular collapse and tumour haemorrhagic necrosis so severe as to cause ulceration of the overlying epidermis. Less severe tumour necrotic patches, which generally resolved with scar formation, are observed in mice injected with 2.5 jig TNFa + 5 x I03 U IFN-y.
Tumour growth was inhibited with daily injections of 2.5 jig TNF-x. (P = 0.01 at 3 weeks, as compared to control, Figure la ). IFN-y (5 x 103 U) alone had no effect. Potentia- tion of the anti-tumour growth effect was achieved with daily injections of 2.5 iLg TNF--in combination with 5 x I03 U IFN-y (Figure la and b, P= 0.003 at 3 weeks, as compared with control; P = 0.049 at 4 weeks, as compared with TNF-a alone). As described above, this regimen was accompanied by the appearance of tumour necrosis. Survival of treated mice was prolonged as compared with controls ( Figure 2 (Figure 3a) . By contrast, tumours in mice treated with 2.5 iLg TNF-a and 25 x I03 U IFN-y showed complete regression after 35 days of therapy (Figure 3b ). Only normal breast ducts and fat cells of mouse origin were present, indicating that tumour cells had not differentiated into breast tissue but had altogether disappeared. Indication of apoptosis and fibrinoid necrosis preceded these changes.
Vascular changes By electron microscopy, numerous capillaries could be found in the host cell stromal reaction area but none in the tumour cell islands. (Figure 4c) . After 24 h tumour capillary endothelial cells had disappeared, although the basal lamnina appeared to be intact (Figure 4d ). Not all capillaries in treated tumours exhibited these changes; some capillaries showed no intraluminal erythrocyte accumulation and in others the basal lamina had disappeared. In general, the areas of vascular damage tended to be focal and associated with areas of tumour cell death. These changes were not observed in normal skin injected with TNF-a and IFN-y nor in tumours treated with either agent alone. No inflammatory cell infiltrates were seen within the tumour mass in either control or cytokine-injected mice.
Apoptosis and necrosis
As shown in Figure 5 , the injection of 2.5 Lg TNF-a and 25 x I03 U IFN--y induced tumour cell death by two distinct mechanisms. Certain cell were clearly apoptotic with characteristic condensation of chromatin around the periphery of the nucleus, together with round, less densely staining therapy ( Figure 6 ). Intercellular adhesion molecule-I (ICAM-1) mRNA was also detected in control tumours and .was strongly induced by either therapy, with maximum mRNA levels appeanrng 3 h after injection, returning to baseline levels after 24 h (Figure 7 ). Vascular cell adhesion molecule-I (VCAM-1) mRNA levels were almost undetectable in control tumours. mRNA expression was induced by either cytokine alone or in combination, with highest VCAM-1 mRNA exppression reached 6 h post therapy. P-selectin mRNA was present in low levels in control tumours and was also rapidly induced by either treatment. Maximum induction was achieved I h after therapy (Figure 7 ). IL-6 mRNA was very strongly induced by TNF-a treatment but not by IFN-y after 1 h. Dual therapy did not affect significantly the expression of IL-6, as compared with TNF-a alone (Figure 7) .
Discus
In the present study we have shown that high-dose human recombinant TNF-x, delivered locally, was able to inhibit tumour growth. Human TNF--x can only act through the 55 kDa receptor but not the 75 kDa receptor in mice (Brouckaert et al. 1993 ). The TNF R 75 kDa has been shown to mediate many of the vascular effects of TNF-a, such as neutrophil adhesion to the endothelium and Eselectin expression (Barbara et al., 1994 , 1994 Eggermont et al., 1993) . However, other groups following the same protocol have not been able to obtain similar results (Vaghni et al., 1994) . Tumour regression in response to TNF-a can be due to direct and indirect effects, many of which may be potentiated by IFN-y. Among its direct effects TNF-a can induce both apoptotic and necrotic forms of cell lysis (Laster et at., 1988; Bellomo et al., 1992) . In the present report, we have shown necrosis and apoptosis of 1068 tumour cells. It is not clear, however, whether necrosis was the direct result of TNF-a, or the indirect result of vascular damage, oxygen starvation, cytotoxic actions of other host stromal cells induced by the therapy or a combination of these. IFN-y, which can also induce either pathological or physiological cell death (Aune and Pogue, 1989) could not have caused tumour cell death directly, since rat IFN--y does not act on human cells.
Vascular damage is now widely accepted as a mechanism of the tumoricidal actions of TNF-a. This cytokine has been reported to have direct cytotoxic effects on the vascular endothelium (Watanabe et al., 1988) , to induce apoptosis of endothelial cells in vitro (Robaye et al.. 1991) and to modulate endothelial procoagulant properties (Nawroth and Stern, 1986 TNF-a and IFN-y can promote the expression of overlapping sets of adhesion molecules (Pober et al., 1986) . Following cytokine therapy, we noted the increased expression of endogenous TNF, TNF receptor 55 kDa. TNF receptor 75 kDa, ICAM-1 VCAM-1, P-selectin and IL-6 mRNA levels. To the best of our knowledge, this is the first extensive study investigating the kinetics of mRNA expression for these cytokines, receptors and adhesion molecules in tumours. In general, low levels of ICAM-1 and VCAM-1 can be observed in normal vascular endothelium and their expression is stimulated by cytokine therapy (reviewed in Bevilacqua 1993). VCAM-1, as well as P-selectin, can also be present in non-vascular cells. Mediators that stimulate Pselectin expression can cause endothelial cell retraction or damage resulting in increased permeability. Furthermore, higher levels of ICAM-1 mRNA in response to TNF-a and IFN-y therapy could be involved in the adherence of platelets to the tumour vascular endothelium and the ensuing damage, by analogy with the pathology observed in the munrne model of cerebral malaria (Grau et al., 1993) . However, this alone cannot account for tumour regression since IFN-y has no activity on its own. ICAM-l can also bind LFA-l-expressing neutrophils and monocytes. When neutrophils adhere to activated endothelium they can secrete proteolytic enzymes which are able to destroy the extracellular membrane (Cajot et al.. 1986 ). The induction and amplification of adhesion molecule expression. namely VCAM-1. ICAM-l and ELAM-l have also been reported in melanoma and sarcoma patients treated with high dose TNF-m. IFN-y and melphalan (Renard et al.. 1994) . The specific induction of IL-6 by TNF-z alone or in combination with IFN-y is of interest. After continuous infusion of TNF-a and IFN-y, elevated circulating levels of IL-6 have been reported (Brouckaert et al.. 1989) . In the study presented here. IL-6 could thus contribute to the antitumoural effect, as shown before in other murine tumour models (Mule et al.. 1990 ). Very recently. increased serum 11-6. ICAM-1 and TNF receptor 55 kDa concentrations have been detected in patients undergoing TNF-a IFN-y melphalan therapy by ILP (Thom et al.. 1995) .
In conclusion, the present study shows that we have been able to produce a useful model of cytokine-induced tumour growth arrest and necrosis. comparable with ILP (Lienard et al.. 1992 ). The differences between human ILP and the present model should however be stressed: in ILP, human TNF-a is injected systemically, in combination with human IFN-y and melphalan. We inject human TNF-a intratumourally and IFN-y systemically. In ILP, a human tumour in a human host is treated, whereas we treat a human xenograft in an immunocompromised mouse. Notwithstanding the limitations imposed by our model. we found it to reproduce certain key aspects of ILP: destruction of tumour cells by necrosis, endothelial cell activation, induction of adhesion molecule expression and specific damage of the tumour vasculature in response to TNF-a and IFN-y therapy. As for ILP, it is tempting to speculate that the association of platelets and neutrophils with areas of vascular injury. via the induction of specific adhesion molecules on the host endothelium. may play a crucial role in mediating these anti-tumoural actions.
